Bioequivalence of Senaparib Manufactured at 2 Sites in Healthy Fasting Subjects
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2025
Bioequivalence Study of 10mg vs 20mg Senaparib Capsules in Healthy Chinese Under Fasting
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2025
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
Details : Paxonin (senaparib) is a PARP 1/2 inhibitor, received NMPA approval as monotherapy for adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian cancer.
Product Name : Paxonin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : IMPACT Therapeutics, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMP4927 (senaparib) is a PARP inhibitor, being investigated as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response or partial response.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : IMPACT Therapeutics, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Senaparib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC
Details : The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Senaparib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact Therapeutics Announces Completion of Series D1 Financing
Details : Proceeds will be used to accelerate the development of its synthetic lethality programs, including IMP4297, which are showing best-in-class potential. The company already has three synthetic lethality compounds in the clinical stage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 14, 2022
Lead Product(s) : IMP9064,Senaparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Burning Rock Dx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Burning Rock will provide the testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, with worldwide intellectual property rights.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 04, 2021
Lead Product(s) : IMP9064,Senaparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Burning Rock Dx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable